circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
The Parliamentary Commissioner for Standards launches an investigation into Democratic Unionist Party MP Sammy Wilson for an alleged breach of lobbying rules after he failed to declare an interest when tabling a question on the Turkish Republic of Northern Cyprus, and following a visit to the area. 16 November – The SNP's National Executive Committee proposes cutting the number of staff at its headquarters from 26 to 16. Ruth Maguire, MSP for Cunninghame South, announces she will not seek re-election at the 2026 Scottish Parliament election because she is to undergo treatment for cancer. Protesters gather outside Welsh Labour's party conference to oppose changes to inheritance tax for farmers outlined in the October budget as Prime Minister Sir Keir Starmer defends the government's changes. 17 November – Sir Ed Davey, the leader of the Liberal Democrats, says that Jane Dodds, who leads the party in Wales, should reflect on her position after a report found she made a "grave error of judgement" in her handling of a sexual abuse scandal when she worked for the Church of England. 18 November – At the 2024 G20 Rio de Janeiro summit, Starmer holds talks with Chinese president Xi Jimping and emphasises the importance of a "strong UK–China relationship" for both countries. 19 November – Scottish Labour leader Anas Sarwar says his party will expand the eligibility for winter fuel payments in Scotland if they win the 2026 Scottish Parliament election.
The episode is now considered to be a serious breach of medical ethics and of the Hippocratic Oath. The government covered up most of these actions until 1993, when President Bill Clinton ordered a change of policy and federal agencies then made available relevant records. The resulting investigation was undertaken by the president's Advisory Committee on Human Radiation Experiments, and it uncovered much of the material about plutonium research on humans. The committee issued a controversial 1995 report which said that "wrongs were committed" but it did not condemn those who perpetrated them.
Furin is a protease, a proteolytic enzyme activated by substrate presentation that in humans and other animals is encoded by the FURIN gene. Some proteins are inactive when they are first synthesized, and must have sections removed in order to become active. Furin cleaves these sections and activates the proteins. It was named furin because it was in the upstream region of an oncogene known as FES. The gene was known as FUR (FES Upstream Region) and therefore the protein was named furin. Furin is also known as PACE (Paired basic Amino acid Cleaving Enzyme). A member of family S8, furin is a subtilisin-like peptidase.
After the Third Partition of Poland in 1795, Poland had ceased to exist as an independent state. From 1795 through the beginning of World War I, several unsuccessful uprisings to regain independence took place. The Great Poland Uprising of 1806 was followed by the creation of the Duchy of Warsaw, which lasted for eight years before it was partitioned again between Prussia and Russia. Under German rule, Poles faced systematic discrimination and oppression. The Poles living in the region of Greater Poland were subjected to Germanisation and land confiscations to make way for German colonization. At the end of World War I, US President Woodrow Wilson's Fourteen Points and the idea of national self-determination were met with opposition from European powers standing to lose influence or territory, such as Germany, which dominated Greater Poland. German politicians had signed an armistice leading to a ceasefire on 11 November 1918. Also, Germany had signed the Treaty of Brest-Litovsk with Bolshevik Russia to settle the territorial boundaries of the eastern frontiers. That treaty took into consideration of a future Polish state and so from then until the Treaty of Versailles was fully ratified in January 1920 many territorial and sovereignty issues remained unresolved. Wilson's proposal for an independent Poland initially did not set borders that could be universally accepted.
Sources: en.wikipedia.org
Robin Harper, a former leader of the Scottish Greens, joins Scottish Labour, citing his former party's failure on the environment for his decision. 12 June – MSPs vote for the early release of 500 prisoners in order to ease overcrowding in the Scottish Prison Service. Edinburgh City Council approves plans by AEG to build an 8,500 capacity stadium at Edinburgh Park. 13 June – Stagecoach Group announces plaans to cut services in north Scotland as it launches a review of its operations. 14 June – Five Scotland fans are taken to hospital after their hire car crashed as they left an airport in Germany driving on the wrong side of the road. The Independent Parliamentary Standards Authority clears Douglas Ross of misusing his travel expenses following an investigation. The 2024 Birthday Honours are published. Among Scots to be recognised are former Prime Minister Gordon Brown, who becomes a Companion of Honour, and footballers Graeme Souness (CBE) and Ally McCoist (MBE). 16 June – Aberdeen City Council cancels the 2024 Highland Games shortly before it is due to commence following "heavier than forecast" rain. 17 June – NHS Dumfries and Galloway warns residents living in the area to assume some of their data has been published online after its database was hacked. 18 June – Scottish Labour launches its general election manifesto. 19 June – The Scottish National Party launches its election manifesto, with plans to "end Westminster cuts" and increase investment in the NHS.
In nuclear engineering, a delayed neutron is a neutron released not immediately during a nuclear fission event, but shortly afterward—ranging from milliseconds to several minutes later. These neutrons are emitted by excited daughter nuclei of certain beta-decaying fission products. In contrast, prompt neutrons are emitted almost instantaneously—within about 10−14 seconds—at the moment of fission. During fission, a heavy nucleus splits into two smaller, neutron-rich fragments (fission products), releasing several free neutrons known as prompt neutrons. Many of these fission products are radioactive and typically undergo beta decay to reach more stable configurations. In a small subset of cases, the beta decay of a fission product results in a daughter nucleus in an excited state with enough energy to emit a neutron. This neutron, emitted shortly after fission but delayed due to the beta decay process, is called a delayed neutron. The delay in neutron emission arises from the time required for the precursor nuclide (the beta-decaying fission product) to undergo beta decay—a process that takes orders of magnitude longer than the prompt emission of neutrons during fission. While the delayed neutron is emitted almost immediately after beta decay, it is actually released by the excited daughter nucleus produced in that decay. Therefore, the overall timing of delayed neutron emission is governed by the beta decay half-life of the precursor. Delayed neutrons are critically important for controlling nuclear reactors.
Venom is produced in a specialised gland (or glands) and is delivered through hollow fangs or a stinger in a process called envenomation. The main function of venom is to disrupt the physiological processes of the wounded animal through neurotoxic, cytotoxic, myotoxic, or haemotoxic mechanisms. This can then help in certain processes such as procuring prey or in defense from predators. Venom has evolved many times in multiple phyla, each having developed their own unique types of venom and methods of delivery independently. However, due to the excessive amounts of venomous animals in the world, they are the major cause of animal-related deaths (~ 57,000 in 2013) than non-venomous animals (~22,000). For example, globally, someone is bitten by a snake every 10 seconds, according to estimates. Snakes are responsible for more than 5.4 million biting-injuries, resulting to 1.8 - 2.7 million envenomings and around 81,410 to 137,880 deaths annually. Bites by venomous snakes can cause acute medical emergencies involving severe paralysis that may prevent breathing, cause bleeding disorders that can lead to fatal haemorrhage, cause irreversible kidney failure and severe local tissue destruction that can cause permanent disability and limb amputation. Children may suffer more severe effects and can experience the effects more quickly than adults due to their smaller body mass. With venomic methods, venom can be co-opted into beneficial substances such as new medicines and effective insecticides.
Sources: en.wikipedia.org
=== Filters === By 1959, Millipore made porous membrane filters of cellulose esters or other materials which resembled paper in sheet form, and were brittle when dry but friable when wet. Filters consisted of nitrocellulose or polycarbonate membrane nucleopore filters ranging from pore size of 0.2 μm (micrometer) to 20 μm. Modern filters are polyvinylidene fluoride and/or polypropylene based.
It is common for photographs, notes, cards, and favourite personal items to be placed in the coffin with the deceased. Bulky and expensive items, such as electric guitars, are occasionally interred with a body. In some ways this mirrors the ancient practice of placing grave goods with a person for their use or enjoyment in the afterlife. In traditional Chinese culture, paper substitutes of the goods are buried or cremated with the deceased instead, as well as paper money specifically purchased for the occasion.
He concluded that there was an internal secretion of the pancreas, but suggested several reasons why it may never be captured in a pancreatic extract. Between 1910 and 1920, techniques for measuring blood sugar (glucose test) were rapidly improved, allowing experiments to be conducted with greater efficiency and precision. These developments also helped establish the notion that high blood sugar levels (hyperglycemia), rather than glycosuria, was the important condition to be relieved. Working at the Rockefeller Institute for Medical Research between 1915–1919, Israel Kleiner reported convincing results on the effect of ground pancreas solutions on blood sugar levels, using rigorous experimental controls which "theoretically... support[ed] the internal secretion hypothesis of the origin of diabetes" and "practically... suggest[ed] a possible therapeutic application." He discontinued this work upon leaving Rockefeller institute in 1919, for reasons not clearly known. Romanian scientist Nicolae Paulescu, another notable figure in the search for the anti-diabetic factor, began experimenting in 1916 using a slightly saline pancreatic solution like Kleiner's. After being interrupted by the Battle of Bucharest and the postwar turmoil, he published his first results in French in 1920 and 1921. His extracts resulted in clear reduction of blood and urinary sugar in the tested dogs, but had no immediate effect in his human patients (through rectal injection) that could not be duplicated by doses of saline alone.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.